Head-to-head · Cost-Efficiency Index
Invigor Medical vs Zeuss
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Invigor Medical
Value shoppers who want competitive pricing on both molecules plus a wider wellness/hormone program on one account.
Visit Invigor MedicalZeuss
Cost-first shoppers who want the only one-time-purchase, no-subscription compounded GLP-1 model.
Visit ZeussThe verdict
Invigor Medical takes it, leading the Cost-Efficiency Index 88 to 67. Solid mid-market cost on both molecules from an established operator — good value if you also want a broader metabolic and hormone catalog. Zeuss still earns a C — Cost-first shoppers who want the only one-time-purchase, no-subscription compounded GLP-1 model.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Invigor Medical.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Invigor Medical | Zeuss |
|---|---|---|
| Cost-Efficiency Index | 88/100 | 67/100 |
| Semaglutide / mo | $199/mo | $125/mo (compounded) |
| Tirzepatide / mo | $339/mo | $175/mo (compounded) |
| Semaglutide / yr (modeled) | $2,388 | $1,500 |
| Tirzepatide / yr (modeled) | $4,068 | $2,100 |
| Coverage | Not disclosed | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Compounded only |
| Rank on the board | #8 | #143 |
Invigor Medical
88/100Where the value is
- Competitive mid-market pricing on both semaglutide and tirzepatide
- Long-running operator with a broad catalog that can consolidate spend
- Both molecules published up front for easy cost modeling
The tradeoffs
- Does not publish an explicit states-served list, so access is a variable in the model
- Compounded only
Zeuss
67/100Where the value is
- One-time-purchase model with no subscription — genuinely rare among DTC GLP-1 providers
- Publishes the FDA compounded-medication disclaimer
- Names both 503A and 503B compounding pathways — uncommon transparency
The tradeoffs
- 503A pharmacy partner not named (only generic '503A and 503B state-licensed' framing)
- LegitScript certification not mentioned
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.